Drug Profile
Anti-CD19 monoclonal antibody - Netherlands Cancer Institute
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Netherlands Cancer Institute
- Developer Nonindustrial source
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD19 antigen inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 09 May 1995 Preclinical development for Cancer in Netherlands (Unknown route)